Do analysts recommend BIOG or IHP?

IntegraFin has a consensus price target of GBX 435, suggesting a potential upside of 16.94%. Given IntegraFin's stronger consensus rating and higher probable upside, analysts clearly believe IntegraFin is more favorable than The Biotech Growth Trust. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score The Biotech Growth Trust 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IntegraFin 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60

Do analysts recommend BIOG or GROW?

Molten Ventures has a consensus target price of GBX 638.67, indicating a potential downside of 5.38%. Given Molten Ventures' stronger consensus rating and higher possible upside, analysts plainly believe Molten Ventures is more favorable than The Biotech Growth Trust. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score The Biotech Growth Trust 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Molten Ventures 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media favor BIOG or GROW?

In the previous week, Molten Ventures had 3 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 4 mentions for Molten Ventures and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.63 beat Molten Ventures' score of 0.49 indicating that The Biotech Growth Trust is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment The Biotech Growth Trust 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Molten Ventures 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

The Biotech Growth Trust (BIOG) Competitors

GBX 1,622 -6.00 (-0.37%)

As of 09/11/2026 12:15 PM Eastern

Compare

BIOG vs. TMPL, IHP, JFJ, GROW, and FCSS

Should you buy The Biotech Growth Trust stock or one of its competitors? The Biotech Growth Trust's main competitors and comparable companies include Temple Bar (TMPL), IntegraFin (IHP), JPMorgan Japanese (JFJ), Molten Ventures (GROW), and Fidelity China Special (FCSS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does The Biotech Growth Trust compare to Temple Bar?

Temple Bar (LON:TMPL) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

10.7% of Temple Bar shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 0.2% of Temple Bar shares are owned by insiders. Comparatively, 1.5% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

The Biotech Growth Trust has a net margin of 96.47% compared to Temple Bar's net margin of 74.06%. The Biotech Growth Trust's return on equity of 48.26% beat Temple Bar's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Temple Bar	74.06%	19.52%	7.08%
The Biotech Growth Trust	96.47%	48.26%	12.39%

Temple Bar has a beta of 1.151, indicating that its stock price is 15% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.577, indicating that its stock price is 42% less volatile than the broader market.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than Temple Bar. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Temple Bar. The Biotech Growth Trust's average media sentiment score of 1.63 beat Temple Bar's score of 0.75 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company	Overall Sentiment
Temple Bar	Positive
The Biotech Growth Trust	Very Positive

Temple Bar has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Temple Bar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Temple Bar	£222.42M	5.70	£154.90M	£75.20	5.49
The Biotech Growth Trust	£133.86M	2.30	£83.83M	£558.00	2.91

Summary

The Biotech Growth Trust beats Temple Bar on 7 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to IntegraFin?

The Biotech Growth Trust (LON:BIOG) and IntegraFin (LON:IHP) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

10.5% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 44.0% of IntegraFin shares are held by institutional investors. 1.5% of The Biotech Growth Trust shares are held by company insiders. Comparatively, 14.5% of IntegraFin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than IntegraFin. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for IntegraFin. The Biotech Growth Trust's average media sentiment score of 1.63 beat IntegraFin's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company	Overall Sentiment
The Biotech Growth Trust	Very Positive
IntegraFin	Neutral

The Biotech Growth Trust has a net margin of 96.47% compared to IntegraFin's net margin of 28.60%. The Biotech Growth Trust's return on equity of 48.26% beat IntegraFin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Biotech Growth Trust	96.47%	48.26%	12.39%
IntegraFin	28.60%	27.60%	20.29%

The Biotech Growth Trust has higher earnings, but lower revenue than IntegraFin. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than IntegraFin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Biotech Growth Trust	£133.86M	2.30	£83.83M	£558.00	2.91
IntegraFin	£165.40M	7.43	£52.54M	£19.10	19.48

The Biotech Growth Trust has a beta of 0.577, meaning that its share price is 42% less volatile than the broader market. Comparatively, IntegraFin has a beta of 1.276, meaning that its share price is 28% more volatile than the broader market.

IntegraFin has a consensus price target of GBX 435, suggesting a potential upside of 16.94%. Given IntegraFin's stronger consensus rating and higher probable upside, analysts clearly believe IntegraFin is more favorable than The Biotech Growth Trust.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Biotech Growth Trust	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IntegraFin	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

IntegraFin beats The Biotech Growth Trust on 10 of the 16 factors compared between the two stocks.

How does The Biotech Growth Trust compare to JPMorgan Japanese?

JPMorgan Japanese (LON:JFJ) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

18.9% of JPMorgan Japanese shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.1% of JPMorgan Japanese shares are held by insiders. Comparatively, 1.5% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than JPMorgan Japanese. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for JPMorgan Japanese. The Biotech Growth Trust's average media sentiment score of 1.63 beat JPMorgan Japanese's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company	Overall Sentiment
JPMorgan Japanese	Neutral
The Biotech Growth Trust	Very Positive

JPMorgan Japanese has a beta of 1.026, indicating that its share price is 3% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.577, indicating that its share price is 42% less volatile than the broader market.

JPMorgan Japanese has a net margin of 96.52% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat JPMorgan Japanese's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JPMorgan Japanese	96.52%	20.00%	8.06%
The Biotech Growth Trust	96.47%	48.26%	12.39%

JPMorgan Japanese has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than JPMorgan Japanese, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JPMorgan Japanese	£245.55M	4.90	£194.81M	£149.06	5.39
The Biotech Growth Trust	£133.86M	2.30	£83.83M	£558.00	2.91

Summary

JPMorgan Japanese beats The Biotech Growth Trust on 7 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Molten Ventures?

The Biotech Growth Trust (LON:BIOG) and Molten Ventures (LON:GROW) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 40.5% of Molten Ventures shares are owned by institutional investors. 1.5% of The Biotech Growth Trust shares are owned by company insiders. Comparatively, 1.6% of Molten Ventures shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Molten Ventures has a consensus target price of GBX 638.67, indicating a potential downside of 5.38%. Given Molten Ventures' stronger consensus rating and higher possible upside, analysts plainly believe Molten Ventures is more favorable than The Biotech Growth Trust.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Biotech Growth Trust	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Molten Ventures	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

The Biotech Growth Trust has higher earnings, but lower revenue than Molten Ventures. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Biotech Growth Trust	£133.86M	2.30	£83.83M	£558.00	2.91
Molten Ventures	£148M	7.88	-£33.58M	£69.00	9.78

In the previous week, Molten Ventures had 3 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 4 mentions for Molten Ventures and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.63 beat Molten Ventures' score of 0.49 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
The Biotech Growth Trust	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Molten Ventures	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

The Biotech Growth Trust has a net margin of 96.47% compared to Molten Ventures' net margin of 75.09%. The Biotech Growth Trust's return on equity of 48.26% beat Molten Ventures' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
The Biotech Growth Trust	96.47%	48.26%	12.39%
Molten Ventures	75.09%	9.21%	-3.46%

The Biotech Growth Trust has a beta of 0.577, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Molten Ventures has a beta of 1.9564402, meaning that its stock price is 96% more volatile than the broader market.

Summary

Molten Ventures beats The Biotech Growth Trust on 10 of the 16 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Fidelity China Special?

Fidelity China Special (LON:FCSS) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than Fidelity China Special. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Fidelity China Special. The Biotech Growth Trust's average media sentiment score of 1.63 beat Fidelity China Special's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company	Overall Sentiment
Fidelity China Special	Neutral
The Biotech Growth Trust	Very Positive

The Biotech Growth Trust has a net margin of 96.47% compared to Fidelity China Special's net margin of 81.41%. The Biotech Growth Trust's return on equity of 48.26% beat Fidelity China Special's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fidelity China Special	81.41%	9.12%	N/A
The Biotech Growth Trust	96.47%	48.26%	12.39%

Fidelity China Special has a beta of 0.919, meaning that its stock price is 8% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.577, meaning that its stock price is 42% less volatile than the broader market.

7.8% of Fidelity China Special shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.1% of Fidelity China Special shares are held by insiders. Comparatively, 1.5% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Fidelity China Special has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Fidelity China Special, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fidelity China Special	£146.54M	7.68	£997.06M	£29.75	8.32
The Biotech Growth Trust	£133.86M	2.30	£83.83M	£558.00	2.91

Summary

The Biotech Growth Trust beats Fidelity China Special on 8 of the 13 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOG vs. The Competition

Export

Metric	The Biotech Growth Trust	Capital Markets Industry	Finance Sector	LON Exchange
Market Cap	£307.95M	£5.50B	£14.01B	£2.87B
Dividend Yield	N/A	7.47%	5.94%	6.23%
P/E Ratio	2.91	30.54	25.67	366.83
Price / Sales	2.30	1,230.74	510.21	83,599.70
Price / Cash	87.74	47.89	40.16	27.89
Price / Book	1.51	3.53	2.75	6.33
Net Income	£83.83M	£418.04M	£1.32B	£5.89B
7 Day Performance	-5.26%	-1.39%	-1.17%	-0.69%
1 Month Performance	-4.92%	-1.45%	0.26%	0.18%
1 Year Performance	74.03%	4.82%	9.27%	20.03%

The Biotech Growth Trust Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOG The Biotech Growth Trust	N/A	GBX 1,622 -0.4%	N/A	+73.3%	£307.95M	£133.86M	2.91	N/A	Positive News High Trading Volume
TMPL Temple Bar	N/A	GBX 418 -0.2%	N/A	+18.2%	£1.28B	£222.42M	5.56	N/A
IHP IntegraFin	N/A	GBX 382.50 -1.0%	GBX 435 +13.7%	+10.9%	£1.26B	£165.40M	20.03	3,520
JFJ JPMorgan Japanese	N/A	GBX 825.22 +0.6%	N/A	+16.7%	£1.24B	£245.55M	5.54	N/A
GROW Molten Ventures	1.4847 of 5 stars	GBX 698 +2.5%	GBX 638.67 -8.5%	+85.4%	£1.21B	£148M	10.12	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:BIOG) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The Biotech Growth Trust (BIOG) Competitors

BIOG vs. TMPL, IHP, JFJ, GROW, and FCSS

How does The Biotech Growth Trust compare to Temple Bar?

Summary

How does The Biotech Growth Trust compare to IntegraFin?

Summary

How does The Biotech Growth Trust compare to JPMorgan Japanese?

Summary

How does The Biotech Growth Trust compare to Molten Ventures?

Summary

How does The Biotech Growth Trust compare to Fidelity China Special?

Summary

Media Sentiment Over Time

BIOG vs. The Competition

The Biotech Growth Trust Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

The Biotech Growth Trust (BIOG) Competitors

BIOG vs. TMPL, IHP, JFJ, GROW, and FCSS

How does The Biotech Growth Trust compare to Temple Bar?

Do insiders & institutionals hold more shares of TMPL or BIOG?

Is TMPL or BIOG more profitable?

Which has more risk and volatility, TMPL or BIOG?

Does the media refer more to TMPL or BIOG?

Which has preferable valuation & earnings, TMPL or BIOG?

Summary

How does The Biotech Growth Trust compare to IntegraFin?

Do insiders & institutionals have more ownership in BIOG or IHP?

Does the media refer more to BIOG or IHP?

Is BIOG or IHP more profitable?

Which has stronger earnings and valuation, BIOG or IHP?

Which has more volatility and risk, BIOG or IHP?

Do analysts recommend BIOG or IHP?

Summary

How does The Biotech Growth Trust compare to JPMorgan Japanese?

Do insiders and institutionals hold more shares of JFJ or BIOG?

Does the media prefer JFJ or BIOG?

Which has more risk and volatility, JFJ or BIOG?

Is JFJ or BIOG more profitable?

Which has stronger valuation and earnings, JFJ or BIOG?

Summary

How does The Biotech Growth Trust compare to Molten Ventures?

Do institutionals and insiders believe in BIOG or GROW?

Do analysts recommend BIOG or GROW?

Which has stronger earnings and valuation, BIOG or GROW?

Does the media favor BIOG or GROW?

Is BIOG or GROW more profitable?

Which has more risk and volatility, BIOG or GROW?

Summary

How does The Biotech Growth Trust compare to Fidelity China Special?

Does the media prefer FCSS or BIOG?

Is FCSS or BIOG more profitable?

Which has more risk & volatility, FCSS or BIOG?

Do insiders & institutionals have more ownership in FCSS or BIOG?

Which has preferable valuation and earnings, FCSS or BIOG?

Summary

Media Sentiment Over Time

BIOG vs. The Competition

The Biotech Growth Trust Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools